Navigation Links
Allegiance Equity Corporation announces collaboration with Canadian Dairy Commission and Guelph Food Technologies Corporation for Alzheimers and Dementia formulation GG-XT
Date:6/23/2008

(TSX-V "ANQ") Canadian Dairy Commission funds formulation of two beverages with GG-XT at

Guelph Food Technologies.

TORONTO, June 23 /PRNewswire-FirstCall/ - The Canadian Dairy Commission has funded the formulation of two dairy beverages with GG-XT for Allegiance at Guelph Food Technologies.

Allegiance filed Canadian and International Patent Applications, and Health Canada Natural Product Applications for GG-XT. GG-XT is a proprietary compound of Panax Gensing and Gingko Giloba for the treatment and prevention of Alzheimers and Dementia. GG-XT improves memory, cognitive function, vitality of life and mental well-being.

Recent Developments

Biofrontera AG of Germany, listed on Frankfurt Stock Exchange (BBF) has licensed Relieva and Psorberine from Prime Pharmaceutical Corporation (Prime). Allegiance has a 37.5% equity interest in Prime as the controlling shareholder.

The licensing of Relieva and Psorberine for the treatment of Eczema and Psoriasis to Biofrontera will rapidly develop product extentions and new channels of commercialization globally when combined with Biofrontera's revolutionary "nano-technology" treatment for acne, eczema, general irritation and inflammation. The transaction in addition to an upfront fee valued at approxiametely $175,000 in Biofrontera shares will augment revenues by a minimum of $240,000 per annum payable against a 5% royalty on net sales.

The strategic business association with Biofrontera AG is an important extension of the impressive worldwide network of partners that Allegiance has developed. This development includes major scientific, research and regulatory organizations, including, world renowned scientists, researchers, universities and suppliers. Allegiance continues to attract an impressive following based on its ability to invent new proprietary treatments for widespread diseases where existing drugs, research channels and OTC products fails to meet the needs of patients. Allegiance has a unique ability for commercializing "peer reviewed" scientific knowledge and abstracts; creating new treatments using standardized pharmaceutical grade natural ingredients.

Biofrontera's association is yet another value-enhancing development for Allegiance and an addition to its existing and growing portfolio of intellectual property that includes:

CM-X is a proprietary compound for treating and preventing diabetes and related cardiovascular conditions which reduces blood sugar, LDL cholesterol, triglicerides and vascular inflammation. CM-X has been formulated into a wide variety of every day foods and beverages such as Heart Chocolate-CM-X. The sales of Heart Chocolate have exceeded expectations and Heart Chocolate is featured in over 200 stores in Canada. For further information see http://www.heartchocolate.ca.

ZX-HDL Formulation is to be developed in partnership with a leading Canadian Cardiologist and Nutrasource Diagnostics Inc. to develop and test ZX in fish oil and Omega Formulas to increase HDL Cholesterol levels.

Allegiance's corporate development program of aggressive product development and continuous sourcing of intellectual property augments its goal of using natural ingredients to maximize profits and minimize risks; while dramatically reducing safety risks for both users as well as investors in its products.

Certain statements contained in this press release may be considered as forward-looking. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from estimated or implied results. The TSX Venture Exchange has neither approved nor disapproved the contents of this new release.

The TSX Venture Exchange has not reviewed and does not accept

responsibility FOR THE ADEQUACY OR ACCURACY FOR THIS PRESS RELEASE, WHICH

HAS BEEN PREPARED BY MANAGEMENT.


'/>"/>
SOURCE Allegiance Equity Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Edwards Lifesciences to Present at the 18th Annual Wachovia Nantucket Equity Conference
2. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
3. Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders Equity Deficiency
4. Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment
5. China Kangtai Cactus Biotech, Inc. Obtains $500,000 Equity Financing
6. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
7. BioMagnetics Diagnostics Corp. Rated Speculative Buy, Target Price $1.42 by Beacon Equity Research
8. Arthrosurface Raises $4 Million of Preferred Equity Financing
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
10. Acrongenomics Acquires Equity Stake in Molecular Vision
11. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):